Biotech innovations, biologics, and gene therapies
Halozyme Therapeutics (HALO) filed an 8-K on January 28, 2026, reporting preliminary, unaudited financial estimates for the year ended December 31, 2025, and providing updated financial guidance for 2...
Amgen filed an 8-K on February 3, 2026, reporting its unaudited results of operations for the fourth quarter and full year 2025.
Eli Lilly and Company filed an 8-K on February 4, 2026, reporting its financial results for the quarter and year ended December 31, 2025. The filing includes a press release (Exhibit 99.
BioMarin Pharmaceutical Inc. (BMRN) announced the pricing of a $850 million private offering of 5.500% senior unsecured notes due 2034.
Bristol Myers Squibb (BMY) reported its fourth quarter and full-year 2025 financial results, highlighting growth in its Growth Portfolio, which includes key drugs like Opdivo, Camzyos, Breyanzi, and R...
BioMarin Pharmaceutical Inc. (BMRN) announced plans to offer $850 million in senior unsecured notes due 2034 in a private offering.